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Viral infections are often detrimental to host survival and reproduction. Consequently, hosts have evolved
a variety of mechanisms to defend themselves against viruses. A component of this arsenal is a set of
proteins, termed restriction factors, which exhibit direct antiviral activity. Among these are several classes
of proteins (APOBEC3, TRIM5, Tetherin, and SAMHD1) that inhibit the replication of human and simian immu-
nodeficiency viruses. Here, we outline the features, mechanisms, and evolution of these defense mecha-
nisms. We also speculate on how restriction factors arose, how they might interact with the conventional
innate and adaptive immune systems, and how an understanding of these intrinsic cellular defenses might
be usefully exploited.Introduction
There are many examples in nature wherein antagonistic coevo-
lution results in rapid adaptation of genes, physiology, and
behavior. Classic examples include those involving relationships
between parasites and hosts or between predators and prey.
Predators possess characteristics such as strong jaws and
sharp teeth; speed, camouflage, and stealth for ambush; and
keen eyesight for hunting. In turn, prey species adapt to sense,
evade, and defend themselves against predators by acquiring,
for example, keen odor detection, tremendous speeds, and
specialized defense structures such as body shells, spines, or
horns. The evolution of these traits is driven by the reciprocal
selective pressures that each group applies on the other. In
a similar way, the invasion of hosts by viruses represents another
example of an antagonistic evolutionary struggle. Because viral
infections are often detrimental to host survival and reproduc-
tion, hosts have evolved a variety of mechanisms to sense,
evade, and defend themselves against a variety of viral threats.
A component of this arsenal is a set of proteins with direct anti-
viral activity. These can be thought of as comprising an autono-
mously functioning, ‘‘intrinsic’’ immune system (Bieniasz, 2004),
or as a specialized component of the conventional innate
immune system. These antiviral proteins, often termed ‘‘restric-
tion factors,’’ inhibit the replication of viruses, which then adapt
to evade and defend themselves against this form of host immu-
nity. Thus, antagonistic conflict begets defense and counter-
defense measures, iteratively shaping viral and host functions
and genomes.
Human and simian immunodeficiency viruses (HIVs and SIVs),
have come to represent amodel system in virology that has been
instrumental in expanding our understanding of how viruses and
hosts interact. In this review, we focus our attention on restriction
factors that are known to inhibit the replication of this group of
viruses, highlighting the features, mechanisms, and evolution
of these defense systems. We also speculate on how these
particular restriction factors arose, how they might interact with
the conventional immune systems and influence the course ofdisease, and how an understanding of intrinsic cellular defenses
might be usefully exploited.
General Features of Restriction Factors
Restriction factors often possess certain properties that differen-
tiate them from most other gene products (Malim and Bieniasz,
2012). Specifically, they (1) are dominantly and autonomously
acting proteins that exhibit antiviral activity in simple cell-
culture-based assays, (2) are often constitutively expressed in
some cell types, but are sometimes upregulated by interferons,
(3) employ unique and unanticipated mechanisms to inhibit
specific processes in viral replication, (4) have unusually diverse
amino acid sequences as a consequence of antagonistic coevo-
lution with viruses, and (5) are often (but not always) antagonized
by viral accessory proteins. There are four currently known
classes of restriction factors that target HIV-1 and other primate
lentiviruses (Figure 1): the APOBEC3 proteins (Sheehy et al.,
2002), TRIM5 proteins (Stremlau et al., 2004), Tetherin (Neil
et al., 2008; Van Damme et al., 2008), and SAMHD1 (Hrecka
et al., 2011; Lahouassa et al., 2012). Five classes of primate lenti-
virus proteins—Vif (Sheehy et al., 2002), Vpu (Neil et al., 2008;
Van Damme et al., 2008), Vpx (Hrecka et al., 2011; Lahouassa
et al., 2012), Nef (Jia et al., 2009; Zhang et al., 2009), and Env
(Gupta et al., 2009b; Le Tortorec and Neil, 2009)—have each
evolved the ability to antagonize a specific antiviral protein
(Figure 1).
Restriction Factors Are Generally Autonomous
Inhibitors of Viral Replication
In general, antiretroviral restriction factors that have been identi-
fied thus far act as simple self-sufficient entities, rather than
being components of complex pathways. Moreover, they act in
a cell-autonomous fashion, i.e., their activity is evident in simple
cell-culture-based viral replication or infectivity assays. Thus,
their existence was indicated by early studies that defined cell
lines to be ‘‘restrictive’’ or ‘‘permissive,’’ depending on whether
wild-type or mutant viral strains could efficiently replicate thereinImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 399
Figure 1. Overview of Restriction Factors that Target HIV and SIV and Their Viral Antagonists
The key mechanisms by which restriction factors directly act upon the retroviral replication cycle, and their counteraction by viral accessory proteins, are
depicted. The process of APOBEC3-mediated hypermutation is indicated in the inset panel.
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between restrictive and permissive cell lines demonstrated that
heterokaryons exhibited the restrictive phenotype, suggesting
a dominant mode of action for putative restriction factors (Malim
and Bieniasz, 2012). In one case, otherwise permissive cells ex-
hibited a restrictive phenotype after treatment with interferon
(Neil et al., 2007). Sometimes, viruses lacking a particular acces-
sory gene failed to complete particular steps in the viral life
cycle, specifically in restrictive cell lines, and it was posited
that the accessory gene was required to antagonize an unknown
inhibitor (Malim and Bieniasz, 2012). These concepts underlined
the design of experiments that led to the identification of
several restriction factors. In each case, expression of a single
gene could convert the phenotype of a cell line from permissive
to restrictive (Sheehy et al., 2002; Stremlau et al., 2004; Neil et al.,
2008; Van Damme et al., 2008; Lahouassa et al., 2012).
Restriction Factors Are Constitutively Expressed or
Induced by Interferons
Adaptive immunity differs from innate (or intrinsic) immunity in
various respects. One key difference is the rapidity with which
restriction factors can exert their effects. T- and B- lymphocyte
receptor diversity is generated via somatic recombination,
meaning that only tiny numbers of cells with antiviral potential
are present at the onset of a new infection. Effector cells are
clonally expanded upon exposure to the pathogen, requiring400 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.several days to weeks to accumulate sufficient numbers to
mount an effective adaptive immune response. In contrast, fully
active forms of restriction factors are encoded in the germline
and are sometimes constitutively expressed. Indeed, prototype
human antiretroviral restriction factors, i.e., APOBEC3G and
TRIM5, were found to be constitutively expressed in cell types
targeted by primate lentiviruses, leading to the notion of
‘‘intrinsic’’ immunity (Bieniasz, 2004), whereby cells, and
perhaps whole organisms, are resistant to infection in the
apparent absence of any signaling event. While it was subse-
quently shown that each of the known primate lentivirus restric-
tion factors can be increased by interferon in some cell types
(Neil and Bieniasz, 2009), IFN-induction is not required for
profound antiretroviral activities to be evident in primate cells.
Thus, although the distinction between intrinsic and innate
immunity may not be as profound as originally envisaged
(Bieniasz, 2004), there is a clear, perhaps biologically critical,
distinction between intrinsic, pre-existing, immunity and inter-
feron-dependent innate immunity.
Restriction Factors Have Diverse Mechanisms of Action
In the case of adaptive immune responses and antiretroviral
drugs that target viral proteins, resistance is most often acquired
through one or a few amino acid substitutions that prevent drug
or antibody binding, or prevent epitope recognition by, or
presentation to, cytotoxic T cells. Like antiretroviral drugs,
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unlike antiretroviral drugs, they do so in a way that makes it diffi-
cult for HIV-1 to evolve resistance to the inhibitor through simple
evasive mutations. Rather, the mechanisms employed by
restriction factors often impose a requirement for the virus to
gain new functions to counter the inhibitor. Themechanisms em-
ployed by restriction factors are diverse, elegant, and unantici-
pated (Figure 1).
Hypermutation
The APOlipoprotein B Editing Catalytic subunit-like 3 family of
proteins includes seven members in humans (APOBEC3A, B,
C, DE, F, G, and H), each of which is characterized by the pres-
ence of cytidine deaminase (CDA) domains (Harris and Lidda-
ment, 2004). APOBEC3G (384 amino acids, 46.4 kDa,
Figure 2A) is the prototype antiretroviral cytidine deaminase
(Sheehy et al., 2002), but several members of this family are
capable of inhibiting retroviral infection. In most cases, antiretro-
viral activity requires that the APOBEC3 protein is expressed in
virus infected cells and incorporated into progeny virions
(Sheehy et al., 2002). In the case of APOBEC3G, the viral nucle-
ocapsid (NC) and associated viral or cellular RNAs that are incor-
porated into virions drive APOBEC3G packaging (Malim and
Bieniasz, 2012). Upon virion entry into a new target cell, APO-
BEC3G acts during reverse transcription, primarily during the
synthesis of the negative sense DNA strand (Yu et al., 2004).
Specifically, cysteine residues in the conserved active site
[(C/H)-X-E-X2328-P-C-X-24-C] coordinate a Zn
2+ ion allowing
the catalytic glutamate to deaminate the C4 position of 20-deox-
ycytidine producing 20-deoxyuridine. Several structures of the
CDA domain of APOBEC3G have been reported, but there are
discrepancies in the conformation of a terminal b strand, b2, as
well as the nature of the DNA binding site (Autore et al., 2010)
(Figure 2B). APOBEC3G preferentially acts on the third cytosine
of the sequence 50-CCCA-30 (Yu et al., 2004) but deviations from
this consensus are tolerated, and a remarkably high fraction (up
to 10% of nascent deoxycytidines) can be deaminated. This
causes major disruption of the coding potential of the viral
genome, generally rendering it replication defective.
Aside from APOBEC3G, several other APOBEC3 proteins,
including APOBEC3A, APOBEC3B, APOBEC3D, APOBEC3F,
and APOBEC3H, can significantly restrict primate lentivirus
infection in in vitro assays (Bishop et al., 2004). While most
work via broadly similar mechanisms to those employed by
APOBEC3G, the other APOBEC3 proteins preferentially catalyze
the deamination of cytidines in a different sequence context to
APOBEC3G and can have different domain organization with
respect to determinants of virion incorporation and catalytic
activity (e.g., APOBEC3H, has only one CDA domain). Notably,
in addition to their hypermutation activity, APOBEC3G and
APOBEC3F can inhibit the accumulation of reverse transcripts
even when mutated to a catalytically inactive form (Newman
et al., 2005), but the precise mechanism underpinning this
activity is yet to be elucidated. In the case of APOBEC3A, a quite
different role in the restriction of primate lentiviruses has been
proposed, whereby APOBEC3A expressed in myeloid target
cells acts on incoming viruses. The principal effect of
APOBEC3A appears to be the reduction in the amount of
viral DNA. Furthermore, SIVMAC Vpx reportedly counteracts
APOBEC3A by inducing its degradation (Berger et al., 2011).Viral Capsid Disruption
TRIM5a (497 amino acids, 57.3 kDa, Figure 2C) is a member of
the TRIpartiteMotif family of proteins that share a common archi-
tecture but have distinct functions. TRIM5a targets the incoming
viral capsid prior to reverse transcription (Stremlau et al., 2004),
and a consequence of restriction is capsid disruption and/or
degradation (Stremlau et al., 2006). TRIM proteins are character-
ized by an N-terminal domain comprising RING, B-box, and
coiled-coil domains. The RING domain of TRIM5a binds two
zinc atoms tetrahedrally and possesses E3 ubiquitin ligase
activity (Figure 2D, left panel). While RING domain mutants
have residual restriction activity, the RING domain greatly
increases antiretroviral potency (Stremlau et al., 2004). B-boxes
are also zinc-binding domains that are unique to the TRIM family
and appear to mediate the formation of higher-order multimers
of TRIM5a (Diaz-Griffero et al., 2009). Notably, certain solvent-
exposed B-box residues are critical for higher-order multimeri-
zation (Figure 2D, right panel) and are also critical for antiviral
activity. Absent the B-box domain, TRIM5 forms dimers, driven
by the coiled-coil domain (Diaz-Griffero et al., 2009). Again,
this intermolecular TRIM5 interaction is required for antiviral
activity.
The C-terminal domain of TRIM5a is a SPRY domain, portions
of which are highly variable among primate species. This domain
contains the determinants that dictate the spectrum of retrovi-
ruses that are restricted by a particular TRIM5 variant and is
almost certainly responsible for directly binding to incoming
retroviral capsids. Indeed, in owl monkeys and macaques,
LINE-mediated retrotransposition events have inserted cyclo-
philin A (CypA) cDNAs into the respective TRIM5 loci (Nisole
et al., 2004; Sayah et al., 2004; Stoye and Yap, 2008). These
insertions result in the expression of fusion proteins known as
TRIMCyp, in which the C-terminal SPRY domain is replaced by
a CypA domain. Several primate lentiviral capsids bind CypA,
and those that do are generally restricted by TRIMCyp proteins.
Notably, owl monkey andmacaque TRIMCyp proteins arose and
have evolved independently, with remodeling of the capsid
binding site on CypA to alter restriction specificity (Price et al.,
2009). It is striking that very similar, intuitively rare, retrotranspo-
sition events leading to the genesis of TRIMCyp proteins have
occurred, and been fixed, at least twice in primate genomes
within the past few million years.
Although it is reasonably clear that direct binding of TRIM5
protein to incoming capsids is required for restriction, subse-
quent events and the mechanistic basis of TRIM5a-mediated
inhibition remain somewhat enigmatic (Sastri and Campbell,
2011). Restriction occurs within minutes of the entry of the viral
capsid into the cytoplasm (Perez-Caballero et al., 2005), reverse
transcription is blocked, and the biochemical behavior of the
capsid protein on sucrose gradients is altered, consistent with
the notion that TRIM5 induces the premature disruption of the
capsid structure (Stremlau et al., 2006). However, both inhibition
of reverse transcription and capsid disruption can be blocked by
the application of proteasome inhibitors, without affecting the
antiviral activity of TRIM5a (Wu et al., 2006). This finding
suggests that the reported biochemical effects are not central
to the mechanism by which TRIM5 proteins inhibit infection.
Intriguingly, a recombinant chimeric TRIM21-TRIM5a protein
self-assembles in vitro into a hexagonal lattice that isImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 401
Figure 2. Structure and Antiretroviral Activity of Restriction Factors
(A) Architecture of APOBEC3G.
(B) Ribbon representation of the C-terminal CDA domain of APOBEC3G (PDB entry 3IR2) consisting of a five-stranded b-sheet core surrounded by six a-helices.
The b2-sheet (shown in green) is distorted to various degrees in all reported NMR (PDB entries 2JYW, 2KBO, and 2KEM) and X-ray structures (PDB entries 3IQS
and 3IR2), due to the differential hydration of residues in each structure. The three flexible loops near the CDA catalytic site (shown in red) contribute to substrate
binding. The residues coordinating the zinc atom (black sphere), either directly or via a water molecule (blue sphere), are shown as a stick representation.
(C) Architecture of TRIM5a.
(D) Left: NMR structure (PDB entry 2ECV; residues 1 to 78) of the RINGdomain of human TRIM5a. The putative E2 enzyme-binding domain is shown in brown. The
residues coordinating the zinc atom (black sphere) are shown as a stick representation. Right: NMR structure (PDB entry 2YRG; residues 86 to 131) of the B-box
domain of human TRIM5a. A hydrophobic cluster of residues (shown in pink) and Arg 119 (shown in green) in particular are critical for higher-order oligomerization.
(E) A proposed model of TRIM5a activity suggests that TRIM5a forms a complementary three-dimensional lattice around the incoming capsid. The RING domain
(green circles), the coiled-coil and B-box domains (black lines), and the SPRY domain (pink rectangles) are indicated.
(F) Architecture of Tetherin.
(G) A model for the possible configurations adopted by tetherin dimers (PDB entry 2XG7) during virion tethering. Tetherin dimers might trap virions by the
incorporation of one pair of anchors into the viral envelope (left and center panels). Alternatively, tethering might be achieved through the multimerization of
tetherin molecules that are distributed between virion envelope and cell membrane (right panel). N and C represent the termini of tetherin.
(H) Architecture of SAMHD1.
(I) Ribbon representation of the HD domain of SAMHD1 (PDB entry 3U1N) with an expanded view of the active site. The residues coordinating the zinc atom (gray
sphere), water molecule (blue sphere) and the phosphate ion are shown as a stick representation.
For (A), (C), (F), and (H), domains andmotifs critical for function are highlighted in color and numbers indicate the amino acid positions. Stars indicate catalytic site
residues.




Reviewcomplementary to that formed by the HIV-1 capsid protein
(Figure 2E) (Ganser-Pornillos et al., 2011) and it is possible that
this activity, in itself, underlies its inhibitory activity. However,
more complex indirect models, involving TRIM5-dependent
signaling (see below), andmobilization of as yet unidentified anti-
viral effectors have also been suggested to underlie the antiretro-
viral activity of TRIM5 (Pertel et al., 2011) (see discussion by
Iwasaki [2012] in this issue).
Tethering Nascent Virions
Tetherin (180 amino acids, 19.7 kDa, Figure 2F; also known as
CD317, BST-2, or HM1.24) is a type II transmembrane protein
that also encodes a C-terminal glycosylphosphatidylinositol
(GPI) anchor. Tetherin traps nascent but mature virions at the
cell surface (Neil et al., 2008; Van Damme et al., 2008), from
where they may be endocytosed. Unlike the other restriction
factors, tetherin exhibits activity against enveloped viruses
from several different viral families (Evans et al., 2010). Structur-
ally, tetherin is composed of a short cytoplasmic N-terminal
domain and an extracellular 170A˚ a-helical domain that is
flanked by the twomembrane anchors. Disulfide bonds between
extracellular cysteines stabilize tetherin dimers in a parallel
coiled-coil conformation, but the N-terminal portion of the coiled
coil appears quite flexible (Weissenhorn et al., 2012). Tetherin is
mainly located in the trans-Golgi network (TGN) and at the cell
surface and appears to continuously shuttle between these
locations.
An engineered protein, constructed from protein domains that
have similar configuration, but almost no sequence homology to
domains found in tetherin, restricts virion release in a similar
manner to wild-type tetherin (Perez-Caballero et al., 2009). This
finding suggests that tetherin (1) acts alone and does not require
cellular cofactors, and, (2) does not recognize a specific viral
protein component. In fact, tetherin is concentrated at sites of
virion budding and is incorporated into the lipid envelope of
virions (Perez-Caballero et al., 2009; Fitzpatrick et al., 2010;
Hammonds et al., 2010). Thus, tetherin probably traps virions
simply by the partitioning of linked membrane anchors between
virion and cell membranes. The specific orientation that the teth-
erin dimer adopts during virion tethering is not entirely clear, but
both the GPI and transmembrane anchors are capable of driving
tetherin incorporation into virions. Moreover, virions become
tethered not only to the cell membrane, but also to each other,
a scenario that is only compatible with the notion that both
membrane anchors can be incorporated into virion membranes.
There are a few configurations that could be adopted by tetherin
during virion tethering (Figure 2G), and which, if any, of these
predominates is yet to be fully resolved.
While tetherin retains viruses on infected cells and thereby
inhibits transmission to distal cells, it may enhance direct cell-
to-cell transmission by concentrating viral particles in the vicinity
of adjacent, uninfected cells. Cell-to-cell transmission is puta-
tively mediated by the formation of virological synapses, i.e.,
concentrations of viral particles at sites of direct contact
between cells. Tetherin-mediated enhancement of this mode
of spread can be observed in vitro (Jolly et al., 2010). However,
an in vivo model for retroviral infection has demonstrated that
tetherin reduces viral burden and inhibits pathogenesis, sug-
gesting that the net effect of tetherin in vivo is to inhibit retroviral
replication (Liberatore and Bieniasz, 2011).Depletion of Deoxynucleotide Triphosphates
Whereas the aforementioned restriction factors directly interact
with viral components (such as genome, capsid, and lipid enve-
lope), the Sterile Alpha Motif- and HD-domain containing protein
1 (SAMHD1) (626 amino acids, 72.2 kDa, Figure 2H) exerts an
indirect antiretroviral effect (Hrecka et al., 2011; Laguette et al.,
2011). Specifically, it reduces intracellular nucleotide concentra-
tions and thus inhibits reverse transcription (Lahouassa et al.,
2012). SAMHD1 is composed of N-terminal SAM domain and
a C-terminal HD domain. SAM domains typically mediate
protein-protein interactions, occasionally forming higher-order
polymers, and can also possess specific RNA binding activity.
HD domains contain conserved histidine and aspartate residues
and are found in metalloenzymes bearing phosphohydrolytic
activity. Indeed, SAMHD1 possesses an unusual phosphohydro-
lytic activity that underlies its ability to inhibit primate lentivirus
infection. Specifically, it is a dGTP-activated triphosphohydro-
lase that hydrolyzes deoxynucleoside triphosphates (dNTPs) to
deoxynucleosides and inorganic triphosphate (Goldstone et al.,
2011; Powell et al., 2011). While all four dNTPs are substrates
of SAMHD1, dGTP promotes its dimerization and acts as both
activator and substrate for the enzyme. The SAMHD1 catalytic
core (Figure 2I) fortuitously crystallizes with a phosphate ion
from the crystallization buffer, marking the putative active site
(Goldstone et al., 2011).
Although lentiviral reverse transcriptases (RTs) have evolved
to replicate under lower concentrations of dNTPs than gammar-
etrovirus RTs, HIV-1 reverse transcribes with slower kinetics in
myeloid cells than in activated T cells (Diamond et al., 2004).
This finding is attributable to expression of SAMHD1 in myeloid
cells, which depletes dNTPs to concentrations below the
Michaelis constant (KM) of HIV-1 RT. Consistent with this notion,
a HIV-1 bearing a mutant RT with lower affinity for dNTPs is
particularly sensitive to SAMHD1-mediated restriction and repli-
cates in activated T cells, but not in myeloid cells (Diamond et al.,
2004; Lahouassa et al., 2012). Moreover, SAMHD1 restriction is
relieved by artificially elevating dNTPs to a concentration at
which reverse transcription can efficiently occur.
Antagonism of Restriction Factors by Viral Accessory
Genes
Presumably because APOBEC3, tetherin, and SAMHD1 target
steps of the viral replication cycle that are virtually unalterable,
and are hence especially difficult to escape via evasive muta-
tions, these restriction factors have driven primate lentiviruses
to acquire specialized countermeasures. In general, these coun-
termeasures involve binding of the restriction factor by a viral
protein, followed by removal of the restriction factor from the
cell, or movement of the restriction factor to a subcellular loca-
tion where it is ineffective. During antagonism, viral proteins
often exploit the normal cellular degradation or transport
machinery. For example, Vif proteins bind to a number of
APOBEC3 proteins and also recruit a cellular ubiquitin ligase
complex composed of cullin5, elongins B and C, and Rbx2 (Yu
et al., 2003). This results in polyubiquitination and subsequent
degradation of APOBEC3 proteins, and effectively denudes cells
of the antiviral protein. A similar mechanism is used by SIV Vpr
and Vpx proteins to remove SAMHD1 from cells, although in
this case, Vpr and Vpx are brought into a newly infected cell asImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 403
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nated from a duplication of the Vpr gene and is only present in
SIVSMM and SIVRCM lineages. At some point in the distant past,
prior to gene duplication, some Vpr genes may have acquired
the ability to degrade SAMHD1 (Lim et al., 2012). Thus, among
modern primate lentiviruses, only some Vpr proteins, but all
known Vpx proteins, have the ability to induce degradation of
SAMHD1. They do so by recruiting a cullin4A-based ubiquitin
ligase complex through a DDB1-DCAF1 adaptor (Le Rouzic
et al., 2007; Schro¨felbauer et al., 2007). Simultaneous Vpr or
Vpx binding to SAMHD1 leads to SAMHD1 ubiquitination and
degradation by proteasomes (Hrecka et al., 2011; Laguette
et al., 2011).
Remarkably, no fewer than three different primate lentiviral
proteins have acquired the ability to antagonize tetherin. HIV-1
Vpu is a small transmembrane protein that interacts, probably
directly, with tetherin via their transmembrane domains (Iwabu
et al., 2009; McNatt et al., 2009; Dube´ et al., 2010). Thereafter,
multiple effects appear to contribute to Vpu’s antagonist activity,
including increased tetherin endocytosis, entrapment of de novo
synthesized, and/or recycling tetherin to the Golgi and tetherin
degradation. (Douglas et al., 2009; Goffinet et al., 2009; Iwabu
et al., 2009; Dube´ et al., 2010; Skasko et al., 2011). Vpu recruits
a b-TrCP-based ubiquitin ligase complex (Margottin et al., 1998)
and induces ubiquitination of the tetherin cytoplasmic tail (To-
karev et al., 2011). This modification and engagement of the
ESCRT pathway (Janvier et al., 2011; Kueck and Neil, 2012)
probably underlies at least some of the aforementioned antago-
nistic effects of Vpu on tetherin.
Many simian immunodeficiency viruses do not encode a Vpu
protein and in these instances, other viral proteins have assumed
the role of tetherin antagonist. Nef is associated with the cyto-
plasmic face of cell membranes and regulates the levels of
a variety of cellular surface proteins including CD4 (Kirchhoff
et al., 2008). Some SIV Nef proteins have acquired the ability
to antagonize tetherin (Jia et al., 2009; Zhang et al., 2009) using
the same basic mechanism that they employ to downregulate
CD4, namely, recruitment of the AP-2 clathrin adaptor complex
and accelerated tetherin endocytosis (Zhang et al., 2011).
HIV-2 also lacks Vpu and has adapted to use its Env protein to
counteract tetherin. HIV-2 Env appears to interact with tetherin
via their respective ectodomains, promoting tetherin internaliza-
tion and/or sequestration (Le Tortorec and Neil, 2009). Interest-
ingly, pathogenic revertants of the normally nonpathogenic
SIVMAC (DNef) arise in rhesus macaques, in which SIVMAC Env
has also adapted to antagonize tetherin (Serra-Moreno et al.,
2011). Curiously, unlike HIV-2 Env, it appears that that SIVMAC
Env cytoplasmic tail interacts with tetherin. These diverse ways
in which primate lentiviruses have adapted to antagonize tetherin
(i.e., employing three different proteins and four apparently
distinct mechanisms) underscore their enormous plasticity and
ability to innovate in response to selective pressures and, in
turn, emphasize the role of tetherin in shaping the evolution of
primate lentiviruses.
Restriction Factors Have Evolved under Positive
Selection
Infectious diseases can serve as potent agents of natural selec-
tion, and it is likely that antagonistic coevolution of interactions404 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.between viruses and their hosts represent a major driver of
evolutionary change in both. Restriction factor variants that
confer an advantage are selected by detrimental viral infections
and can become widespread or even fixed in the host popula-
tion. The resulting reduction in viral fitness in the newly adapted
host provides the impetus for the selection of viral variants that
have acquired mutations or new functions that relieve restriction
and restore fitness. Iterative cycles of this genetic conflict consti-
tute amolecular ‘‘arms race’’ and can result in the rapid evolution
of restriction factors and their viral targets or antagonists
(Figure 3A).
A molecular arms race between protein-coding genes often
means that mutations that change the amino acid sequence
(nonsynonymous mutations) are fixed more frequently than
those that do not (synonymous mutations). Selection of benefi-
cial alleles is termed diversifying or positive selection and
contrasts with purifying or negative selection in that the latter is
driven by the need to preserve protein function through the elim-
ination of deleterious mutations. If multiple cycles of positive
selection drive the evolution of a protein-coding gene, then non-
synonymous mutations (dN) are observed more frequently than
synonymous mutations (dS) in alignments of genes, portions of
genes, or individual codons (dN/dS > 1). As intuitively expected,
the majority of human genes have evolved under purifying
selection (dN/dS < 1) but a subset have evolved under positive
selection (Figure 3B) (Chimpanzee Sequencing and Analysis
Consortium, 2005; Meyerson and Sawyer, 2011). Genes that
exhibit signatures of positive selection include those involved
in sensory perception, probably driven by temporal or migra-
tion-induced changes in the need to sense such things as envi-
ronment, food, or predators. Predictably, positively selected
genes also include those involved in immune responses and
pathogen defense (Kosiol et al., 2008), including restriction
factors. Notably, APOBEC3G and TRIM5a have among the high-
est dN/dS ratios of all human genes (Sawyer et al., 2004, 2005;
Song et al., 2005) (Figure 3B).
Positive selection typically acts on domains or codons that
participate in the interaction between proteins and their targets.
For restriction factors, positive selection can be driven by the
advantage conferred by increased binding to a viral target or
decreased binding to a viral antagonist. For example, portions
of TRIM5a that bear the signatures of positive selection are
found only in the SPRY domain, which directly binds to the
incoming retroviral capsid (Sawyer et al., 2005; Song et al.,
2005). In the case of tetherin, the overall dN/dS ratio is quite
low (Figure 3B), but portions of its coding sequences in the cyto-
plasmic tail and transmembrane domain that are targeted by
viral antagonists have evolved under positive selection (Gupta
et al., 2009a; McNatt et al., 2009). Similarly, SAMHD1 sequences
that are determinants for Vpx sensitivity also exhibit positive
selection (Laguette et al., 2012; Lim et al., 2012).
Notably, the extent to which positive selection is observed in
restriction factors could, in principle, be masked by biochemical
constraints. For example, the transmembrane domain of tetherin
is targeted by HIV-1 Vpu, which could drive positive selection,
yet the need to maintain a hydrophobic helical character prob-
ably drives purifying selection of the same sequence. Moreover,
the virus-driven appearance of positive selection requires
a specific circumstance—namely, recurrent challenges to
Figure 3. Evolution of Restriction Factor and Accessory Gene Function
(A) Nef proteins of SIVs antagonize tetherin by interacting with the tetherin cytoplasmic tail. The diagram is a schematic representation of the genetic conflict
between them. Colored figures indicate tetherin sequences in the cytoplasmic tail that are recognized by Nef and are hence rapidly evolving under positive
selection.
(B) Cumulative frequency distribution of dN/dS ratios for 12,404 human-chimpanzee orthologous gene pairs. Adapted from previously computed data (Chim-
panzee Sequencing and Analysis Consortium, 2005). Positive selection (dN/dS > 1) and purifying selection (dN/dS < 1) are indicated by purple and orange arrows,
respectively. The dN/dS value for each restriction factor is indicated by the dotted lines. The percentage of orthologous gene pairs with lower dN/dS ratios is
indicated by the solid lines.
(C) Evolution of Vpu and Nef function as primate lentiviruses were transmitted between species. See text for details.
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Thus, the mere presence or absence of signatures of positive
selection in a given gene cannot, by itself, be construed as diag-
nostic of the presence or absence of a virus-host interaction.
Nevertheless, each of the four classes of HIV and SIV restriction
factors exhibits signatures of positive selection over at least
a portion of its sequence, in at least some mammalian lineages.
Intrinsic Cellular Defenses Are Determinants of Viral
Host Range
Positive selection causes high interspecies protein sequence
variability in restriction factors. Consequently, viral adaption to
antagonize or evade a particular restriction factor variant in one
host species can come at the cost of susceptibility to restriction
factor variants in another potential host. Thus, antagonistic
coevolution of virus and a particular host can reduce the proba-
bility that an individual viral species can evade or antagonize the
array of defense mechanisms that confront it when the opportu-
nity to colonize a new host species arises.Blocks to cross-species transmission are imposed by
APOBEC3G and TRIM5 proteins that appear particularly power-
ful, perhaps because (1) these two restriction factors are espe-
cially potent inhibitors, and (2) they are constitutively expressed
in the natural target cells of primate lentiviruses. HIV-1 and SIV
Vif proteins are universally capable of antagonizing APOBEC3G
proteins in their natural hosts but are often impotent when con-
fronted with APOBEC3G proteins from other primates (Mariani
et al., 2003; Malim and Bieniasz, 2012). Indeed, the inability of
many SIV Vif proteins to induce degradation of human
APOBEC3G might explain why many SIVs have not been found
in humans. Notably, SIVCPZ Vif and SIVSMM Vif are both active
against human APOBEC3G (Gaddis et al., 2004), and both of
these lineages have successfully colonized humans (as HIV-1
and HIV-2, respectively).
Although human TRIM5a is largely ineffective as an inhibitor of
primate lentiviruses (Kratovac et al., 2008), TRIM5a variants
found in monkeys can be very potent inhibitors, and those found
in some species are capable of restricting an impressivelyImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 405
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fact that many monkey species harbor primate lentiviruses indi-
cates that blocks imposed by TRIM5a can be overcome via
adaptation of the capsid protein. Tetherin and SAMHD1 may
also impede cross-species transmission of primate lentiviruses.
Vpu and Nef proteins are generally only able to antagonize teth-
erin from a restricted range of species. For example, most
HIV-1 Vpu proteins antagonize human tetherin but are inactive
against monkey tetherin proteins (Gupta et al., 2009a; McNatt
et al., 2009). Moreover, whereas SIV Nef proteins are often active
against tetherin variants found in their natural host species, none
are active against human tetherin, due to the deletion of five
amino acids in the human tetherin cytoplasmic tail (Jia et al.,
2009; Zhang et al., 2009). In fact, a rather interesting series of
adaptations appears to have occurred as primate lentiviruses
were transmitted from species to species en route to colonizing
humans, as HIV-1 (Figure 3C) (Sauter et al., 2009). Specifically,
SIVCPZ, the immediate ancestor of HIV-1, arose (in chimpanzees)
through recombination between two SIV lineages found in
monkeys upon which chimpanzee prey, one of which employs
Vpu as a tetherin antagonist while the other employs Nef. Adap-
tation of the recombinant SIVCPZ in chimpanzees resulted in the
selection ofNef as the tetherin antagonist and the loss of tetherin
antagonist function by Vpu. However, upon transmission to hu-
mans, SIVCPZ encountered a tetherin in which the Nef target
site was deleted and, presumably as a consequence, Vpu adapt-
ed to regain a lost function andantagonizehuman tetherin (Sauter
et al., 2009). Provocatively, analysis of the Vpu proteins from
HIV-1 groups M, N, and O reveals that only the Vpu protein of
HIV-1Mstrains have fully evolved to efficiently antagonize human
tetherin, as well as retain its function of CD4 downregulation
(Sauter et al., 2009). It is possible that this factor might have
contributed to the relative success of this viral lineage in
spreading through human populations. Species-specific
SAMHD1-degrading activities are also evident among Vpr and
Vpx proteins (Laguette et al., 2012; Lim et al., 2012) and some
Vpx and Vpr appear to have specialized to deal with SAMHD1
variants that are present in the natural host species. However,
SAMHD1 may not be an especially powerful barrier to cross-
species transmission, because HIV-1 apparently lacks the ability
to antagonize human SAMHD1, yet has spread globally in human
populations. Rather, the ability or otherwise of a particular
primate lentivirus to antagonize SAMHD1 may determine the
extent to which myeloid cell types are infected within a given
host species.
Perspectives and Questions about Restriction Factors
What Are the Origins of Antiviral Factors?
While the aforementioned restriction factors share some
common properties, their mechanisms of action and evolu-
tionary origins are utterly different from each other. How did
such a diverse array of antiviral proteins arise? In principle,
restriction factors could arise de novo as completely new genes,
or through redirection of existing genes that have antiviral poten-
tial. In the case of tetherin, it is difficult (albeit not impossible) to
imagine a precursor gene with a cellular function—there are no
known cellular proteins that have related sequence, structure,
or function, and tetherin appears to be present only in mammals.
Moreover, tetherin is not expressed in the vast majority of cells406 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.unless they are treated with interferon, and mice that lack a teth-
erin gene have no obvious deficiencies (Liberatore and Bieniasz,
2011). Thus, the absence of homologous genes and dispens-
ability for viability are consistent with the notion that tetherin
arose de novo, purely as an antiviral gene.
Alternatively, restriction factors may arise through relatively
minor adaptations of existing cellular activities that have pre-ex-
isting potential to inhibit viral replication. The APOBEC3 family is
probably derived from duplicated copies of cytidine deaminases
(AID and APOBEC1) that have specific roles in editing cellular
DNA and RNA. Thus, in this case, a normal cellular function
was simply redirected to hypermutate viral genomes. In a similar
manner, one might imagine that enzymatic regulation of cellular
dNTP levels by SAMHD1 might have served some important
regulatory function that was subsequently exploited by cells to
inhibit the replication of retroviruses (and perhaps other DNA
viruses). TRIM5 probably represents an intermediate example,
whereby genes with some pre-existing, but mechanistically
unrelated, function were mutated to a form with antiretroviral
activity. Consistent with this idea, most of the dozens of TRIM
proteins do not possess intrinsic antiretroviral activity, but two
examples, TRIM1 and TRIM34, can exhibit weak antiretroviral
activity when overexpressed (Yap et al., 2004; Zhang et al.,
2006). Moreover, a variety of TRIM genes, that otherwise lack
antiretroviral function, can be endowed with anti-HIV-1 activity
if their C-terminal SPRY domains are replaced with cyclophilin
A (Yap et al., 2006; Zhang et al., 2006). These data suggest
that the architecture of TRIM proteins, perhaps a propensity to
assemble hexameric lattices (Ganser-Pornillos et al., 2011),
lends itself to the acquisition of antiretroviral activity.
Are There More Restriction Factors to Be Discovered?
A number of lines of evidence hint at the existence of undiscov-
ered antiretroviral factors that target primate lentiviruses. First,
certain cell types and cell lines are resistant to lentiviral infection,
dependingon their stateof differentiation and/or interferon induc-
tion (Goujon and Malim, 2010), and it is entirely plausible, even
likely, that this resistance is due to the expression of unknown
restriction factors. Second, it is well known that Vpr has the ability
to induce the degradation of proteins to which it binds (Schro¨fel-
bauer et al., 2005). While the role of some SIV Vpr proteins
appears to be the removal of SAMHD1 from cells (Lim et al.,
2012),many other Vpr proteins lack the ability to induceSAMHD1
degradation, suggesting that another target for Vpr-induced
degradation exists. Vpr is dispensible for HIV-1 replication in
cell culture and SIVMAC replication in vivo (Gibbs et al., 1995),
but humans and chimpanzees infectedwith HIV-1 strains encod-
ing defective Vpr proteins develop revertant mutants (Goh et al.,
1998). Thus, Vpr may degrade a restriction factor that is only
encountered in vivo, and it has only amodest effect on the overall
level of viral replication. Finally, the poorly understood ability of
Nef to increase the intrinsic infectiousness of primate lentivirus
particles (Chowers et al., 1994; Miller et al., 1994) could well be
due to antagonism of a restriction factor, particularly given the
known propensity of Nef to downregulate various cell-surface
proteins. Large-scale RNAi and cDNA expression screens (Brass
et al., 2009; Schoggins et al., 2011) are beginning to uncover the
range of proteins that inhibit the replication of a variety of viruses
and it seems likely that the identification of additional proteins
with antiretroviral activity will be forthcoming.
Immunity
ReviewHow Did Viral Infections in the Distant Past Shape the
Array of Modern Restriction Factors?
Although restriction factors are most frequently studied because
of their ability to inhibit modern, clinically important retroviruses,
their existence inmodern genomes is the result of selection pres-
sures imposed by viruses in the distant past. Most retroviral
lineages are long extinct, but some ancient retroviruses are
‘‘fossilized’’ in modern genomes, through their ability to infect
germline cells and become inherited in a Mendelian manner.
Although the viral fossil record probably represents only a small
fraction of the retroviruses that have ever existed, the increasing
availability of genome sequences and convenience of gene
synthesis have made it possible to reconstitute ancient retroviral
proteins, or even complete retroviruses in functional form (Dew-
annieux et al., 2006; Lee and Bieniasz, 2007). These advances
have enabled attempts to reconstruct evolutionary history and
illuminate how restriction factors evolved into their modern
forms. Although the incompleteness of the retroviral fossil record
urges circumspection in the interpretation of such studies, it has
been possible to suggest scenarios by which ancient hosts and
viruses interacted.
For example, reconstitution of ancient lentiviral capsid
proteins from endogenous sequences in lagomorphs and
prosimians indicates that the ability of retroviral capsids to
bind CypA was acquired millions of years ago (Goldstone
et al., 2010). Indeed, it is plausible that CypA binding was wide-
spread, perhaps the norm among ancient lentiviruses. Given the
apparent absence of CypA binding in any other retroviral lineage,
ancient CypA-binding lentiviruses might have been responsible
for fixation of TRIMCyp encoding genes in owl monkeys and
macaques, even though lentiviruses are not known to be present
in these two modern species.
Other examples of ancient host-virus interactions involve
APOBEC3 proteins where hypermutation can be readily
observed in fossilized proviruses. Specifically, APOBEC3G
was clearly responsible for the hypermutation and inactivation
of two HERV-K proviruses in the human genome (Lee et al.,
2008). Furthermore, there are many gammaretrovirus genomes
in chimpanzee, macaque, and murine genomes that were inacti-
vated by APOBEC3G and other APOBEC3 proteins (Jern et al.,
2007; Perez-Caballero et al., 2008).
Although these examples illustrate how it has been possible to
infer interactions between hosts and viruses, it has not yet been
possible to unequivocally demonstrate that specific past retro-
viral infections were responsible for the acquisition, or evolution
of any particular restriction factor. Nor has it been possible to
demonstrate that any particular restriction factor was respon-
sible for extinction of any retrovirus. The sparse nature of the viral
fossil record may make such definitive findings impossible to
achieve. However, this is an active area of research, and it is
even possible that reconstitution and study of ancient retrovi-
ruses might uncover novel restriction factors to which modern
retroviruses have become resistant.
How Might Restriction Factors Interact with Other
Immune Functions?
Because several restriction factors interact with and alter the fate
of virions and virion components, they have the potential to
modify innate and adaptive immune responses. Additionally,
they are, in principle, positioned to recognize pathogen-specificmolecular patterns and perhaps directly participate in triggering
innate immune signaling pathways. Alternatively, the action of
restriction factors could alter the spectrum of cells that become
infected (e.g., specific protection of myeloid cells by SAMHD1),
and in so doing alter the way that viral components are pre-
sented to the innate and adaptive immune systems, as dis-
cussed in an accompanying review (Iwasaki, 2012, this issue).
Moreover, in addition to directly inhibiting viral infection,
TRIM5a appears to trigger signaling pathways. Indeed, the
UBC13-UEV1A E2 ubiquitin-conjugating enzyme interacts with
human TRIM5a to generate the formation of K63-linked ubiquitin
chains that are unattached to substrates (Pertel et al., 2011).
These ubiquitin chains can activate the AP-1 and NF-kB
signaling pathways, potentially leading to cytokine production
and modulation of innate and adaptive immune responses as
discussed in an accompanying review (Iwasaki, 2012, this issue).
Whether other restriction factors, such as tetherin, that directly
interact with virions can initiate signaling cascades is under
investigation.
Tetherin might affect immune responses because of the
substantial effect it has on the fate of virions, concentrating
them on the surface of infected cells, from where a significant
fraction can be endocytosed (Neil et al., 2008; Van Damme
et al., 2008). Depending on which cell type is infected, this
phenomenon could well affect how virion proteins are presented
to the immune system on MHC-II molecules. Alternatively, inter-
nalization could increase the exposure of virion components to
endosomal Toll-like receptors (TLRs), e.g., TLR7, which is known
to respond to endocytosed HIV-1 particles (Beignon et al., 2005).
Conversely, by inhibiting infection ofmyeloid cells, dendritic cells
in particular, SAMHD1-mediated restriction might reduce the
exposure of HIV-1 to TLRs as well as yet undiscovered cyto-
plasmic sensors in these cells (Manel et al., 2010) as discussed
in an accompanying review (Iwasaki, 2012, this issue). Again,
this might affect how innate and adaptive immune systems are
mobilized, with the potential for both positive and negative
effects on host and virus.
Does Variation in Restriction Factors Contribute to AIDS
Susceptibility in Humans?
There is apparently wide variation among humans in the sensi-
tivity to, and the outcomes of, viral infection. While at least
some of the variation in HIV/AIDS susceptibility in humans can
be attributed to CCR5 and MHC polymorphisms, variation in
these genes does not entirely account for variation in AIDS
susceptibility, and it is also possible that genetic variability in
restriction factor loci might also contribute. Subpopulations of
humans encode inactivating or destabilizing lesions in genes en-
coding TRIM5a (Torimiro et al., 2009), APOBEC3B (Kidd et al.,
2007), and APOBEC3H (OhAinle et al., 2008; Harari et al.,
2009). There is also variation among APOBEC3H haplotypes in
terms of their sensitivity to antagonism by Vif. Additionally,
more subtle polymorphic mutations are found in TRIM5a
(H43Y) that decrease activity in in vitro assays (Sawyer et al.,
2006), as well as in APOBEC3G (H186R) (An et al., 2004).
Unfortunately, attempts to link the restriction factor polymor-
phisms with altered HIV/AIDS susceptibility in humans have
yielded contradictory results. This is true for anAPOBEC3B dele-
tion (An et al., 2009; Itaya et al., 2010), the TRIM5a (H43Y) muta-
tion (vanManen et al., 2008; Liu et al., 2011), and theAPOBEC3GImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 407
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2005). In each case, studies showing polymorphism-associated
alteration in HIV-1 infection rate or disease progression have
been contradicted by studies showing no effect, or even
opposing effects. It is unclear whether the lack of concordance
in these studies is due to methodological problems or to genuine
race-based modifying effects. Conversely, in rhesus macaques,
wherein the variation in the sequence and activity of restriction
factors appears more extensive, there is clear evidence that
TRIM5a polymorphisms can affect the course of SIV infection.
Specifically, a group of TRIM5 alleles (designated TRIM5TFP),
and in some cases TRIMCyp, appear to suppress SIV replication
in vivo while others (designated TRIM5Q) are essentially inactive
(Kirmaier et al., 2010; Lim et al., 2010). In some cases, TRIM5
variants select changes in SIV capsid sequences conferring
resistance to TRIM5 restriction in vivo (Kirmaier et al., 2010).
Can Knowledge of Restriction Factors Aid the
Development of Better Animal Models of AIDS?
The formidable barriers to zoonotic transmission imposed by
restriction factors have very likely protected humans from poten-
tially lethal viral pandemics that originate in nonhuman animals.
Reciprocally, HIV-1 cannot replicate in most nonhuman animals,
including nonhuman primates (NHP). Because NHP models of
HIV-1 infection could serve as better platforms to evaluate
drug and vaccine candidates prior to human clinical trials, an
appreciation of how variation in restriction factors limits cross-
species transmission has guided the construction of simian-
tropic HIV-1 (stHIV) strains that encode SIVMAC capsid and Vif
sequences (to evade and antagonize macaque TRIM5a and
APOBEC3 proteins). These stHIV-1 strains replicate well in
macaque cells leading to the conclusion that these two restric-
tion factors constitute major barriers to cross-species primate
lentivirus transmission (Hatziioannou et al., 2006). Fortuitously,
pigtailed macaques encode a TRIMCyp protein that cannot
restrict HIV-1 (Virgen et al., 2008). Consequently, stHIV-1 stains
in which the only alteration is to substitute SIVMAC Vif sequences
can successfully mount a spreading infection in pigtailed
macaques (Hatziioannou et al., 2009). Although stHIV-1-infected
pigtailed macaques do not yet develop disease, there is clear
potential for the development of improved models of human
AIDS based on engineered resistance to restriction factors.
Can an Understanding of Restriction Factors Be
Exploited Therapeutically?
A possible consequence of the increased understanding of
restriction factors is the prospect that they might be mobilized,
or otherwise exploited, in the context of new therapies. For
example, inhibiting the antagonistic effect of accessory proteins
might usefully mobilize the activity of antiviral restriction factors.
Although suchwork is clearly in its infancy, small-molecule inhib-
itors of Vif-mediated APOBEC3G degradation have been identi-
fied that inhibit HIV-1 replication in vitro (Nathans et al., 2008;
Cen et al., 2010). In principle, conceptually similar approaches
could be used to inhibit Vpu-tetherin interactions and mobilize
the latter’s antiviral activity. An alternative approach is to mimic
or potentiate the effects of restriction factors. For instance,
a small-molecule inhibitor of HIV-1 (PF74) that seems to promote
premature viral uncoatingmimics the action of TRIM5a (Shi et al.,
2011). Finally, artificially engineered restriction factors to which
HIV-1 is sensitive could be considered for use in gene therapy408 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.approaches. As a proof of principle, engineered TRIMCyp or
tetherin proteins assembled from human components (Neagu
et al., 2009; Perez-Caballero et al., 2009) have been demon-
strated to have activity against HIV-1 in vitro.
In conclusion, the identification of restriction factors that
inhibit primate lentiviruses and the elucidation of the means by
which they act, evolve, and affect the biology of hosts and
viruses has been a rich scientific endeavor. Although much
remains to be learned, there is clear, albeit yet to be realized,
potential for restriction factors to be exploited for practical
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